The Gaucher’s Disease Treatment Market was valued at US$1.51 billion in the year 2018 and is estimated to reach US$1.67 billion by 2026, at a CAGR of 1.22%.
Gaucher’s Disease (GD), is an autosomal recessive disorder characterized by the accumulation of fatty substances especially in the liver, spleen, lungs, kidney and bone marrow due to mutation of the GBA gene that encodes for the enzyme β-glucocerebrosidase. GD is more common among the Jewish (Ashkenazi) population with a prevalence of about 1 in 450, while in the general population, the prevalence is about 1 in 40, 000.
GD is differentiated into Type I, II and III depending on the extent of damage and involvement of the central nervous system. Type I is more common among the North American, Latin American and European countries; whereas type 3 is more prevalent in other regions of the world. Type I is a non-neuronopathic type where brain stems and abnormalities are not observed and the average lifespan is over 65 years. Both Type II and III are distinguished with the occurrence of brain abnormalities & impairment accompanied by neuronopathic pain. Type I & III are treatable wherein Type II is an irreversible type and fatality occurs within the first 2 years of occurrence in the infants due to the severity of brain damage.
Lately, the incidence of GD is on the rise and the efforts to identify the individuals affected by GD are also on the rise, which is expected to drive the market growth during the forecast period. However, the cost of treatment and lack of late-stage pipeline drugs are set to hinder the market growth. Additionally, challenges like treatment for addressing the neuronopathic pain, unavailability of diagnosis modalities, treatment for pediatric GD, definitive routes of administration and lack of proper treatment schedules can be denoted as the factors which may deter the market growth. However, the recent development in the European region and government organization to focus more on R&D activities of rare diseases are expected to fuel and shape the market.
The major share of GD medication sales is held by the North American region especially the U.S. where the incidence of GD and diagnosis is high. Also, major pharmaceutical companies turn their attention towards the U.S. market based on landscape availability with technical advancements, market penetration, governmental policies, etc. The reign of the U.S. region is expected to extend throughout the forecast period owing to an increase in the awareness of the disease and the number of patients.
The main treatment regimens available for treating GD are enzyme replacement therapy (ERT) through intravenous administration and substrate reduction therapy (SRT) that encompasses oral administration to reduce glucocerebroside production. ERT holds the major market share backed by blockbusters Cerezyme from Sanofi Genzyme, Vpriv from Takeda and Elelyso Pfizer with Cerezyme holding the major market share. But owing to the type of administration and improper schedules, ERTs are said to face a setback in the form of SRTs such as Cerdelga from Sanofi and Zavesca from Actelion. Also, Takeda’s Vpriv holds a 10-year market exclusivity for the European market while Pfizer Elelyso lost the race due to regulatory approval failure. Also, some organizations focus on developing viable delivery platforms for drug delivery for GD. This is expected to change the landscape of the GD treatment market. The market is primarily driven by partnerships, acquisitions, and deals for the development of viable therapeutics.
The key market players who hold a share in the market include Sanofi Genzyme, Pfizer, Shire (acquired by Takeda), Actelion Pharmaceuticals Ltd (acquired by Jannsen), Orphazyme, Amerigen, and more 10+ companies.
The present market analytics report on Gaucher’s Disease from Optima Insights is a part of the First Series on Rare Metabolic Disorders consisting of a detailed analysis on the epidemiology, products, pipeline drugs, key drivers & restraints, challenges, reimbursement policies on the inherited metabolic disorders that require more attention. Further, every part of the rare metabolic disorder series will cover 10 disorders categorized based on country prevalence and occurrence.
The Gaucher’s Disease Market Report is segmented based on Disease Type (Type I, II & III), By Therapy (Enzyme Replacement Therapy & Substrate Replacement Therapy) and By Region (North America, Europe, APAC and LAMEA).
Research Scope
- Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments of Gaucher’s Disease Treatment Market.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products of Gaucher’s Disease Treatment Market.
- Provides Key Information on Players involved.
- Provides a Complete Overview of Market Segments and the Regional Outlook of Gaucher’s Disease Treatment Market.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Gaucher’s Disease Treatment Market, 2015 to 2017
- Forecast of the Gaucher’s Disease Treatment Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Gaucher’s Disease Treatment Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: info@optimainsights.org
https://www.optimainsights.org
